share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  2024/08/01 04:11

Moomoo AI 已提取核心訊息

Teva Pharmaceutical Industries reported Q2 2024 revenues of $4,164 million, up 7% year-over-year, driven by higher generic product sales across all segments and increased AUSTEDO revenues. Net loss narrowed to $846 million from $872 million in Q2 2023, despite a $400 million goodwill impairment charge related to the API business.Gross profit increased 13% to $2,024 million, with gross margin expanding to 48.6% from 46.3% last year, primarily due to a favorable product mix. R&D expenses rose 12% to $269 million as Teva continued executing its Pivot to Growth strategy. The company generated free cash flow of $324 million, down from $632 million in Q2 2023.Teva maintained its full-year 2024 outlook and announced plans to divest its API business, expected to complete in H1 2025. The company also disclosed an ongoing material weakness in internal controls related to contingent consideration accounting, which it is working to remediate through enhanced procedures and controls.
Teva Pharmaceutical Industries reported Q2 2024 revenues of $4,164 million, up 7% year-over-year, driven by higher generic product sales across all segments and increased AUSTEDO revenues. Net loss narrowed to $846 million from $872 million in Q2 2023, despite a $400 million goodwill impairment charge related to the API business.Gross profit increased 13% to $2,024 million, with gross margin expanding to 48.6% from 46.3% last year, primarily due to a favorable product mix. R&D expenses rose 12% to $269 million as Teva continued executing its Pivot to Growth strategy. The company generated free cash flow of $324 million, down from $632 million in Q2 2023.Teva maintained its full-year 2024 outlook and announced plans to divest its API business, expected to complete in H1 2025. The company also disclosed an ongoing material weakness in internal controls related to contingent consideration accounting, which it is working to remediate through enhanced procedures and controls.
梯瓦製藥發佈了2024年第二季度收入爲416400萬,較去年同期增長7%,主要受益於所有板塊的仿製藥銷售增長和AUSTEDO收入的增加。淨虧損縮減至84600萬,低於2023年第二季度的87200萬,儘管與API業務相關的40000萬的商譽減值費用仍在。\n毛利潤增加了13%,達到202400萬,毛利率從去年的46.3%擴大至48.6%,主要是由於良好的產品組合。研發費用增長了12%,達26900萬,因爲梯瓦繼續執行其增長轉型策略。公司生成的自由現金流爲32400萬,低於2023年第二季度的63200萬。\n梯瓦維持其2024年全年的展望,並宣佈計劃剝離其API業務,預計將在2025年上半年完成。公司還披露了在與或有對價會計相關的內部控制中存在的持續重大薄弱環節,正在通過加強程序和控制進行整改。
梯瓦製藥發佈了2024年第二季度收入爲416400萬,較去年同期增長7%,主要受益於所有板塊的仿製藥銷售增長和AUSTEDO收入的增加。淨虧損縮減至84600萬,低於2023年第二季度的87200萬,儘管與API業務相關的40000萬的商譽減值費用仍在。\n毛利潤增加了13%,達到202400萬,毛利率從去年的46.3%擴大至48.6%,主要是由於良好的產品組合。研發費用增長了12%,達26900萬,因爲梯瓦繼續執行其增長轉型策略。公司生成的自由現金流爲32400萬,低於2023年第二季度的63200萬。\n梯瓦維持其2024年全年的展望,並宣佈計劃剝離其API業務,預計將在2025年上半年完成。公司還披露了在與或有對價會計相關的內部控制中存在的持續重大薄弱環節,正在通過加強程序和控制進行整改。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息